(Mount Laurel, NJ; July 10, 2012) – CRI Lifetree opened a new state-of-the-art, early stage research facility in Marlton, N.J. The new site raises the company’s total bed count to 250 and adds capacity to conduct complex clinical trials.
CRI Lifetree, a leader in specialized early stage research focused in pain, human abuse liability, psychiatry, neurology and diabetes, announced its new location to the drug development industry at the 2012 Drug Information Association (DIA) Annual Meeting held June 24-28 in Philadelphia.
“Because our facility is so close to Philadelphia, DIA gave us the opportunity to show many clients the site firsthand. The feedback was overwhelmingly positive!” noted Larry Brownstein, CRI Lifetree’s head of corporate development.
Brownstein added, “The recent visitors were pleased to see we have expanded our research space with this new, 60-bed, purpose-built facility.”
The additional bed space and added capabilities for conducting complex neurology, pediatrics and normal healthy patient studies comes at a time of considerable need for the industry. Other facility features include six beds dedicated to first-in-human studies. This space has an observation area to allow clinicians and sponsors the access needed. The new center also has separate areas for elderly and pediatric populations. The 21,000-square-foot building adds to CRI Lifetree’s two other facilities in Philadelphia and Salt Lake City.
CRI Lifetree, formerly CRI Worldwide and Lifetree Clinical Research®, is a leader in specialized, multitherapeutic inpatient and outpatient early stage research.
